By Bruce D. Callander
Things have changed. They used to stand you in line,
give you two or three shots, and off you went. Nobody
asked what they were for." So said Army Col. Gaston
Randolph, director of DoD's hugely controversial Anthrax
Vaccine Immunization Program.
Randolph was attempting to explain why the services'
effort to vaccinate the troops against deadly anthrax
has generated more controversy than any previous immunization
program.
"There has been a ... shift in the relationship
between health care providers and patients," he
noted. "No longer do you just put a patient in
a doctor's office or in a shot line. We have been empowering
patients with education so that they can make informed
judgments about whether they want this, that, or some
other kind of treatment. We see that in the military,
too." He went on, "You have to tell them
what they are getting and what side effects they might
expect. They ask questions, and they expect answers,
and rightfully so."
Col. Deneice Van Hook, chief of the Air Force Surgeon
General's Prevention Division, noted, too, that perceptions
about the anthrax shots are different from those of
other shots.
"There is," she said, "a much higher
emotional response to this vaccine. You have to understand
that we are giving people an immunization that they
see as a biological warfare agent. That alone scares
people, and I understand that emotional response."
Understanding or not, Van Hook bluntly declared, "There
is no science to support their fear."
The words of Secretary of Defense William S. Cohen: "We
determined that vaccination is the safest, most reliable
way to protect our service members from a potential
threat that is 99 percent lethal to unprotected, untreated
individuals."
Fervent Reassurance
Despite frequent and fervent official Pentagon reassurances
of this type, the vaccination program has drawn intense
fire from many quarters, including Congress. Opponents
say the problem is not emotionalism or faulty perceptions
but questionable medicine and heavy-handed management.
One prominent critic is Rep. Christopher Shays (R-Conn.),
chairman of the House Government Reform subcommittee
on national security, veterans' affairs, and international
relations. His panel carried out an oversight investigation
of the program and, in February, issued a report questioning
both the safety and effectiveness of the shots. It
argued that DoD should designate the vaccine as experimental
and suspend mandatory immunizations until an improved
vaccine is available.
Rep. Walter Jones (R-N.C.) of the House Armed Services
Committee followed up with a letter to President Clinton,
asking him to heed the recommendations and use his
powers as Commander in Chief to halt the program.
Several exchanges between the Pentagon and the lawmakers
followed, but the Defense Department stood firm on
its vaccination program.
Another major critic is Rep. Dan Burton (RInd.),
the chairman of the House Committee on Government Reform.
In October, Burton announced that his committee would
hold new hearings on the vaccination program. While
he acknowledged that DoD has scaled back the shots
because of shortages, he said it had not complied with
Congressional requests for suspension.
In his announcement, Burton added, "An increasing
number of individuals are suffering life-altering injuries
from the vaccine."
At Burton's request, the General Accounting Office,
a Congressional watchdog agency, surveyed Air National
Guard and Air Force Reserve Command pilots and crew
members, asking them what reactions they had to the
vaccine and what effect the immunization program had
on their career decisions.
GAO had mailed 1,253 questionnaires to members. By
early October, the GAO issued a preliminary report
to the committee on the survey on the 828 Guard members
and Reservists who had responded to the survey.
The GAO reported:
AVIP gets scant support. While respondents had positive
attitudes toward immunizations in general, 65 percent
reported that they had little or no support for the
Pentagon's anthrax program. Only 17 percent said they
thought information presented on the DoD Web site was
accurate. And almost nine out of 10 respondents said
they probably would have safety concerns about vaccines
for other biological warfare agents.
Physical reactions are underreported. Of those respondents
who had taken the shots, 86 percent said they had local
or systemic reactions. This percentage is higher than
that reported by service officials. GAO said that some
60 percent of its respondents explained that they didn't
report their reactions. Of these, almost half claimed
that they feared ridicule, loss of flight status, or
adverse impacts on their military or civilian careers.
The vaccinations are hurting retention. About 25 percent
of respondents had switched units (most to take nonflying
jobs), gone to inactive status, or quit the military
within the past two years. While they cited factors
such as family reasons and job opportunities among
the factors, GAO said, "When asked to rank the
one most important factor, the anthrax immunization
was the highest." Another 18 percent of those
who are still in the service said they planned to leave
within six months and also cited the anthrax vaccine
program as the top reason.
The statistical significance of this survey is somewhat
murky. Some defenders of the anthrax program have noted
that the GAO survey was based on a relatively small
sample. In its report, the GAO notes that this was
only a pretest of the questionnaire and that they had
only 828 respondents, of whom only 42 percent (about
348) had actually had any shots. Moreover, all of the
respondents were self-selected and therefore could
not be said to comprise a truly random sample.
Internet Megaphone
The debate over the program has found its way to the
Internet as well. "One of the biggest lessons
we have learned," said Randolph, "is that
you should never underestimate the power of the Internet
to inform and misinform. It used to be that protesters
made posters, put on marches, and maybe ran ads in
newspapers with limited audiences. Now, they can go
worldwide, and in an instant, the information is available
to millions."
To defend the program, AVIP opened its own Web site
(www. anthrax.osd.mil). It presents what it believes
are the facts about the disease and the vaccine and
provides links to other government and private sources
of information.
Officials often direct USAF members to a site called "Virtual
Flight Surgeons Inc." at www.aviationmedicine.com.
The site is run by civilians, Randolph said, but some
are in the reserves as well. When a number of ANG and
AFRC pilots refused vaccination for fear it would lead
to their being grounded from their airlines jobs, the
group went out to the airlines, interviewing not only
people in operations but the medical directors.
The flight surgeons give a balanced discussion of
the vaccine but conclude that flight crew members have
nothing to fear either in their military status or
civilian jobs.
Lt. Col. Susan Northrup, chief of operational medicine
in the USAF Surgeon General's office, said she often
refers skeptical crew members to the site for reassurance.
She added, "I'm a flight surgeon myself, and we
have not seen reaction rates any higher than with any
other vaccine. By and large, our pilots are taking
these and doing just fine."
Randolph concedes the services underestimated the
anxiety that rated members would have about the vaccinations.
"Pilots and other people on flight crews have
very special health requirements," he said. "The
absence of being ill is very important to them. ...
We probably should have recognized early on that, as
with other health issues, fliers were going to have
some unique concerns."
Northrup agreed. She said, "If you worried about
whether something that you were required to take might
affect your being allowed to do what you love to do,
you'd probably raise questions, too. They also are
concerned about whether they can support their families.
But I have not heard of any individuals who have had
their civilian airline jobs threatened."
Few Real Refusals
Resistance to the vaccinations has attracted widespread
press coverage, but officials note that only a relative
handful of members actually had refused the injections.
As of August, they said, there had been a total of
441 refusals, including 129 in the Air Force. Most
refusers have received nonjudicial punishment, said
Randolph. A limited number have gone to court-martial,
most of them in the Marines, but the majority have
been administratively separated, he said.
"The feeling is that this is basically a refusal
of an order," said Randolph, "and each case
is handled separately by the local commander."
Van Hook suggested, too, that not all those who raise
questions actually refuse the shots. According to her, "There
are lots of folks who initially say, 'I'm not going
to take the immunization,' but when we go through a
full one-on-one education program, they realize there
is nothing to fear and go ahead and take the shots.
So we don't want to call those people refusers."
The extent of adverse physical reactions to the vaccine
itself also has been exaggerated, the officials said.
"They have been very similar to other vaccines
in terms of the reactions you would commonly expect," said
Randolph. "It's closest to that for tetanus, and
of course, millions and millions of people have had
tetanus shots. I'm talking about redness, a little
pain at the injection site, swelling, and other things
such as that."
He went on, "In terms of systemic reactions,
the shots seem to be consistent with other vaccines
as well. But, again, we are talking about minor reactions
that are self-limiting and don't require hospitalization
or loss of work time. Generally, you take an over-the-counter
pain medication and you're just fine. There have been
no deaths and no long-term chronic or life-threatening
illness."
Two Million Doses
Van Hook gave a breakdown of the reported reactions
for all services. As of September, she said, the services
had immunized 487,098 people, injecting 1,947,053 doses
of vaccine. Over the period, 1,152 reactions have been
reported and reviewed by an expert civilian panel.
It determined that 592 were "certainly or probably" caused
by the anthrax vaccine.
Of the 592 reactions linked to the vaccine, Van Hook
said, 469 were classed as minor, meaning the members
didn't lose any duty time or have to be hospitalized.
Another 114 members did lose some duty time, most of
them because of reactions at the injection site. Others
had manifestations such as rashes, flu-like symptoms,
intestinal problems, and itchiness.
"Only 10 were actually hospitalized," said
Van Hook, "and all were due to allergic inflammatory
reactions at the injection site."
She added, however, "There have been several
studies that seem to indicate that females are more
apt to have reactions than males, but we really don't
know what's causing that. That gender difference is
one of the things we have asked the Center for Disease
Control to investigate."
Overall, however, the reports so far have come as
a welcome surprise to officials. Van Hook said, "Actually,
the adverse reaction rate is lower than we would have
anticipated with most vaccines. It's very low and the
serious adverse reaction rate is extremely low with
this vaccine."
In recent months, the controversy over the vaccine
has cooled a little. The Pentagon's efforts to put
out more information may be one reason, but it also
could be because there has been a slowdown in the vaccination
program itself.
The problem is in the supply of the vaccine. The services
rely on a single provider, BioPort Corp. of Michigan.
The firm has been expanding and, during the process,
has halted production.
"Until they receive approval for their newly
renovated vaccine facility from the Food and Drug Administration," said
Randolph, "we have a finite amount of stockpiled
vaccine that was produced earlier. So we have had to
slow down the program."
According to a July 17 policy letter signed by Rudy
de Leon, the deputy secretary of defense, those deployed
for at least 30 days to the high-risk theaters of Southwest
Asia and Korea will continue to be vaccinated. Vaccinations
for personnel deploying to these areas should begin
prior to arrival in theater and are authorized to begin
up to 45 days prior to deployment.
"We're vaccinating only people who are forward
deployed in the two high-threat areas of Southwest
Asia and Korea," Randolph said.
While the shortage will interrupt the vaccination
schedule for other members, officials say those who
already have begun the series of shots won't have to
start over.
Van Hook said current service guidelines say members
who have had only one shot given more than two years
ago will have to restart the series. Those who have
had two can pick up where they left off.
That guideline is consistent with other immunizations,
she said. "Say, for example, that we start a woman
out on hepatitis B vaccine, which requires three shots,
and she gets pregnant," said Van Hook. "We
delay immunization until after she is through with
her pregnancy, but we don't restart the series."
When the program resumes its former pace, officials
said, all members will receive an initial series of
six shots over 18 months, followed by an annual booster.
At the moment, the booster shots have been suspended
except for members headed into high-risk areas.
Back on Schedule
If all goes well, the services should have no trouble
getting back on schedule by early 2001. Randolph said, "We
have enough to get us through about spring of next
year with the current slow-down rules. We estimate
that somewhere between January and the end of March,
we'll have that FDA approval of the newly renovated
vaccine suite and we'll have more vaccine."
Even though it cannot release more vaccine at the
moment, BioPort continues to produce it. "As part
of the FDA approval process, they have to produce new
vaccine in the renovated facility," said Randolph. "Three
lots have to come out successfully. So approval also
would be approval of three lots of vaccine and each
lot has about 200,000 doses in it."
All this assumes there are no major hitches in the
approval schedule, however. Against the possibility
of further problems, AVIP has contingency plans that
include developing additional sources of the vaccine.
The program's critics have questioned its safety and
effectiveness. One recurring allegation is that the
shots were responsible for the maladies commonly termed
Gulf War Illness. That charge was fueled in 1994 by
Congressional testimony from the Army's Surgeon General
Lt. Gen. Ronald R. Blanck. He said that the "anthrax
vaccine should continue to be considered as a potential
cause for the undiagnosed illnesses in Persian Gulf
military personnel." Blanck later retracted the
statement and said there is no link between the shots
and the problems reported by Desert Storm veterans,
but it is still a live issue.
The decision to halt production of the vaccine also
was taken by some critics as evidence that the shots
are risky. But Randolph insists it was not FDA that
ordered the interruption in delivery of the shots. "Early
on," he said, "we realized that the original
facility would not be large enough to handle the volume
of production we needed and approved an expansion of
what then was [Michigan Biologics Product Institute].
It is the renovation, which requires new FDA approvals,
that has caused the vaccine shortage."
When stocks allow the services to resume their normal
shot schedules, debate over the vaccine may heat up
again, but officials close to the immunization program
have no doubts about its importance or safety. Said
Van Hook, "I've had four of the shots myself.
I didn't have any reaction other than that associated
with a little lump in my arm. If there were enough
vaccine, I would give it to my child today."
Bruce D. Callander, a regular contributor to Air Force
Magazine, served tours of active duty during World War
II and the Korean War. In 1952, he joined Air Force Times,
serving as editor from 1972 to 1986. His most recent
story for Air Force Magazine, "Virtual Military
Personnel Flight," appeared in the October 2000
issue.